Research Department

Aman Hospital and Research Center

COVID-19

Dyssomnias

Ovarian Epithelial Carcinoma

Prostatic Cancer

Syndrome

Ovarian Cancer

Communicable Diseases

Infections

Sickle Cell Anemia

Parasomnias

Doxorubicin Hydrochloride

Degarelix

S-217622

Vedic Lifesciences

Ayana Pharma

Ferring

Shionogi

condition

allSponsorName

ProRelix Services

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

A total of 170 patients male or female who are carrying SS or Sbeta0 versions of the beta globin gene will be included in the study. The subjects will be assigned with 1:1:1 ratio of either NUV001 Immediate release IR or NUV001 Gastro resistant GR or Placebo. The treatment duration of the study will be 90 days which has in total 5 visits. The primary end point of this study is to check the safety and tolerance of the orally administered nutraceutical supplement. This endpoint will be checked by assessing the Adverse events, Vital signs of the subject and the Change in hematological parameters from Baseline to Final visit.

Safety and Efficacy of Orally Administered NUV001 Nutraceutical Supplement in Sickle Cell Disease Patients

Aman Hospital and Research Center | Research Department

Site insights

Work at this site?

Active trials

Safety and Efficacy of Orally Administered NUV001 Nutraceutical Supplement in Sickle Cell Disease Patients

Trial sponsors